The Whale That Isn't: Why Selling to the NHS Is Harder Than It Looks

From a distance, the NHS looks like a whale.

A single, enormous customer. 1.5 million employees. £180 billion annual budget. Unified branding, a shared mission, and a population of 70+ million people who all use the same healthcare system. For a MedTech founder or investor, the logic seems obvious: land the NHS, and you've landed the UK.

But as you get closer, the whale dissolves. What looked like one massive organism is actually a shoal of hundreds of smaller fish, each swimming in its own direction. And each one needs to be caught with slightly different bait.

This is one of the most expensive lessons in UK healthcare innovation. Companies burn through years of runway and millions in funding before they fully understand it.

The NHS is not a single purchasing entity. It is a federation of over 200 NHS trusts, each operating as an independent statutory body with its own board, budget, and priorities. Add in 42 Integrated Care Boards, hundreds of GP practices, community services, mental health trusts, and arm's length bodies, and you have a system that is unified in name but fragmented in practice.

What this means for anyone trying to sell into it:

There is no single buyer. A contract with one trust gives you no automatic access to another. The decision-maker at Trust A may have never heard of you, even if Trust B, just up the road, has been using your product for many years.

Priorities differ wildly. One trust may be desperate for theatre efficiency tools because they are haemorrhaging money on cancelled operations. The trust next door may have no interest because their bottleneck is bed capacity, not surgical throughput. Same technology, completely different appetite.

Procurement processes vary. Some trusts run rigorous formal tenders. Others rely on framework agreements. Some will trial new technology through innovation budgets. Others require full business cases through multiple committees before a trial is set-up or a penny is spent.

Evidence requirements are inconsistent. What counts as "sufficient evidence" in one trust may be dismissed as inadequate in another. Some want randomised controlled trials. Others will accept real-world data from a comparable site. A few will pilot based on clinical enthusiasm alone.

The result: every trust is effectively a new market entry. The playbook that worked in Manchester may fail completely in Bristol.

Most founders come from industries where landing a large customer means you have landed that customer. Win a contract with Tesco, and you are in Tesco stores. Win a contract with Barclays, and you are in Barclays branches.

The NHS does not work this way. There is no central procurement function that rolls out approved products across the system. NHS England can endorse, recommend, and even mandate certain technologies, but actual purchasing decisions still happen at trust level, filtered through local budgets, local priorities, and local relationships.

This mismatch between expectation and reality creates a dangerous pattern. Companies raise funding based on a total addressable market that assumes NHS-wide adoption. They price their product expecting volume. They build sales teams sized for a national rollout. Then they discover that "the NHS" is actually 200 separate sales cycles, each requiring its own clinical champion, its own business case, and its own procurement journey.

The burn rate stays the same. The revenue arrives far more slowly than projected.

Companies that seem to succeed in the NHS tend to share a few characteristics. They are not necessarily the ones with the best technology. They are the ones who understood the market structure early enough to build for it.

They find clinical champions, not just customers. A product adopted because a procurement team ticked a box will struggle to spread. A product adopted because a respected clinician advocated for it has a chance of being noticed elsewhere. Clinical networks, Royal Colleges, and specialty associations are how word travels in the NHS. Companies that invest in relationships with influential clinicians, rather than just sales calls to procurement, tend to fare better.

They make their evidence portable. If your pilot at one trust produces outcomes data, package it in a form that another trust can use to justify their own adoption. Case studies, health economic analyses, implementation guides. The easier you make it for the next trust to say yes, the shorter their decision cycle becomes.

They target regional clusters rather than going national too early. Integrated Care Systems, and acute provider collaboratives are increasingly coordinating across trusts within their geography. If you can demonstrate value in one trust within an ICS, you have a better chance of spreading to neighbouring trusts than leapfrogging to the other end of the country. Regional density beats national scatter.

They pursue NHS England endorsement as a shortcut, not a guarantee. Getting onto an NHS England approved list, or securing NICE guidance, or being featured in a national programme like the AI and Digital Regulations Service does help. It lowers the perceived risk for individual trusts. But it does not remove the need for local sales. It just makes each conversation slightly easier.

They build for interoperability from day one. Trusts are wary of adding yet another standalone system to their already fragmented IT estate. Products that integrate with existing workflows and existing systems face less resistance. Products that require parallel data entry, new logins, or separate reporting dashboards get stuck in pilot purgatory.

Selling to the NHS is not impossible. Thousands of companies do it successfully. But it requires accepting that you are not selling to one customer. You are selling to hundreds, one at a time, with each sale informing but not guaranteeing the next.

The companies that struggle are the ones who built their strategy around the whale. The companies that succeed are the ones who learned to fish.